sprite-preloader
Anzeige
Mehr »
Samstag, 20.10.2018 Börsentäglich über 12.000 News von 596 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen
12.10.2018 | 15:22
(3 Leser)
Schrift ändern:
(0 Bewertungen)

PR Newswire·Mehr Nachrichten von PR Newswire

STOCKHOLM, Oct. 12, 2018 /PRNewswire/ --

Oncoinvent announces that Radspherin research findings will be presented at the 32nd Annual Congress of the European Association of Nuclear Medicine (EANM) (13-17 October 2018, Düsseldorf, Germany).

The presentation is entitled:

Alpha-Emitting Radiopharmaceutical for IP Therapy of Peritoneal Metastases: In Vitro Evaluation and Therapeutic Effects in a Murine Model

Authors: T. B. Bønsdorff, E. Napoli, I. S. Jorstad, S. Westrøm, Ø. S. Bruland, R. H. Larsen

Session: EP-55 - Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development - Preclinical and translational aspects - Preclinical aspects - Animal models and in-vitro studies

Abstract No.: EP-0788

Format: Electronic poster

CONTACT:

For further information, please contact:

Jan A. Alfheim, Chief Executive Officer
Cell: +47-46-44-00-45
Email: Alfheim@oncoinvent.com

IR enquiries:
Ole Peter Nordby, Chief Financial Officer
Cell: +47-41-28-71-79
Email: nordby@oncoinvent.com

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/oncoinvent-as/r/oncoinvent-to-present-and-attend-the-32nd-annual-congress-of-the-european-association-of-nuclear-med,c2643484

The following files are available for download:

http://mb.cision.com/Main/15403/2643484/925754.pdf

PDF


© 2018 PR Newswire